ImmunityBio (NASDAQ:IBRX) Trading Down 4%

ImmunityBio, Inc. (NASDAQ:IBRX) traded down 4% on Monday . The company traded as low as $4.93 and last traded at $5.06. 2,654,094 shares were traded during trading, a decline of 34% from the average session volume of 4,007,505 shares. The stock had previously closed at $5.27.

Wall Street Analysts Forecast Growth

Separately, Piper Sandler boosted their price objective on ImmunityBio from $4.00 to $5.00 and gave the stock a “neutral” rating in a research note on Monday, March 25th.

ImmunityBio Stock Up 11.1 %

The company has a market cap of $3.72 billion, a PE ratio of -4.73 and a beta of 1.23. The stock has a 50-day simple moving average of $5.19 and a 200 day simple moving average of $4.14.

ImmunityBio (NASDAQ:IBRX) last posted its earnings results on Tuesday, March 19th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.01). The business had revenue of $0.14 million during the quarter, compared to the consensus estimate of $0.03 million. As a group, research analysts anticipate that ImmunityBio, Inc. will post -0.68 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in IBRX. Aire Advisors LLC acquired a new position in shares of ImmunityBio during the 3rd quarter worth about $25,000. WINTON GROUP Ltd acquired a new stake in shares of ImmunityBio in the 3rd quarter valued at about $26,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of ImmunityBio in the 3rd quarter valued at about $37,000. Meridian Management Co. acquired a new stake in shares of ImmunityBio in the 4th quarter valued at about $46,000. Finally, Tower Research Capital LLC TRC boosted its position in shares of ImmunityBio by 43.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 9,393 shares of the company’s stock valued at $47,000 after purchasing an additional 2,844 shares during the period. 8.58% of the stock is owned by institutional investors and hedge funds.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies.